{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:57:14Z","timestamp":1793141834674,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,22]],"date-time":"2027-02-22T00:00:00Z","timestamp":1803254400000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.brachy.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T21:01:34Z","timestamp":1765918894000},"page":"386-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8554","authenticated-orcid":false,"given":"S","family":"Fattahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-3289","authenticated-orcid":false,"given":"CL","family":"Deufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-4265","authenticated-orcid":false,"given":"KV","family":"Astafurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TW","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SL","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Neben Wittich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WS","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JK","family":"Viehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"LA","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IA","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KS","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2025.11.011_bib0001","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.011_bib0002","first-page":"241","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye Lond Engl"},{"issue":"8","key":"10.1016\/j.brachy.2025.11.011_bib0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.brachy.2025.11.011_bib0004","first-page":"304","article-title":"The Collaborative Ocular Melanoma Study: an overview","volume":"11","author":"Margo","year":"2004","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/cancers14010134","article-title":"New perspectives for eye-sparing treatment strategies in primary uveal melanoma","volume":"14","author":"Bilmin","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.brachy.2025.11.011_bib0006","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18","volume":"119","author":"Diener-West","year":"2001","journal-title":"Arch Ophthalmol Chic Ill"},{"issue":"3","key":"10.1016\/j.brachy.2025.11.011_bib0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000455872","article-title":"Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose","volume":"3","author":"Echegaray","year":"2017","journal-title":"Ocul Oncol Pathol"},{"issue":"8","key":"10.1016\/j.brachy.2025.11.011_bib0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/bjo.64.8.565","article-title":"Pattern of mortality in choroidal malignant melanoma","volume":"64","author":"Packard","year":"1980","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.brachy.2025.11.011_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0039-6257(97)00088-X","article-title":"Radiation therapy for choroidal melanoma","volume":"42","author":"Finger","year":"1997","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.brachy.2025.11.011_bib0010","first-page":"886","article-title":"Mortality in patients with small choroidal melanoma. COMS report no. 4. the collaborative ocular melanoma study group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"9","key":"10.1016\/j.brachy.2025.11.011_bib0011","first-page":"1202","article-title":"Plaque radiotherapy for choroidal melanoma encircling the optic disc (circumpapillary choroidal melanoma)","volume":"125","author":"Sagoo","year":"2007","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"11","key":"10.1016\/j.brachy.2025.11.011_bib0012","first-page":"1515","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients","volume":"126","author":"Sagoo","year":"2008","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.011_bib0013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ophtha.2010.06.007","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases","volume":"118","author":"Sagoo","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.011_bib0014","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamaophthalmol.2014.111","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases","volume":"132","author":"Sagoo","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.011_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","article-title":"Visual outcome at 4 years following plaque radiotherapy and prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for uveal melanoma: comparison with nonrandomized historical control individuals","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.brachy.2025.11.011_bib0016","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjophthalmol-2019-314686","article-title":"Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients","volume":"104","author":"Dalvin","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.brachy.2025.11.011_bib0017","first-page":"609","article-title":"Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma","volume":"117","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.011_bib0018","first-page":"837","article-title":"Response of the normal eye to high dose radiotherapy","volume":"10","author":"Parsons","year":"1996","journal-title":"Oncol Williston Park N"},{"issue":"9","key":"10.1016\/j.brachy.2025.11.011_bib0019","first-page":"1219","article-title":"Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"10","key":"10.1016\/j.brachy.2025.11.011_bib0020","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/IAE.0000000000002440","article-title":"Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases: the 2020 Taylor R. Smith and Victor T. Curtin lecture","volume":"39","author":"Shields","year":"2019","journal-title":"Retina Phila Pa"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brachy.2020.09.007","article-title":"EyeDose: an open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for 125I Collaborative Ocular Melanoma Study eye plaques","volume":"20","author":"Deufel","year":"2021","journal-title":"Brachytherapy"},{"issue":"12","key":"10.1016\/j.brachy.2025.11.011_bib0022","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19","volume":"109","author":"Jampol","year":"2002","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.011_bib0023","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.brachy.2018.07.002","article-title":"Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review","volume":"17","author":"Le","year":"2018","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0024","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijrobp.2014.01.026","article-title":"Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes","volume":"89","author":"Perez","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.11.011_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajo.2017.11.008","article-title":"Efficacy and safety of low-dose iodine plaque brachytherapy for juxtapapillary choroidal melanoma","volume":"186","author":"Oellers","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"Electronic address: paulfinger@eyecancer.Com, ABS \u2013 OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.11.011_bib0027","unstructured":"AAPM recommendations on medical physics practices for ocular plaque brachytherapy: report of task group 221 - Thomson - 2020 - Medical Physics - Wiley Online Library. Accessed July 29, 2024. https:\/\/aapm.onlinelibrary.wiley.com\/doi\/10.1002\/mp.13996"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.011_bib0028","first-page":"1254","article-title":"Ocular complications following I-125 brachytherapy for choroidal melanoma","volume":"23","author":"Wen","year":"2009","journal-title":"Eye Lond Engl"},{"issue":"10","key":"10.1016\/j.brachy.2025.11.011_bib0029","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.04-0066","article-title":"Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques","volume":"45","author":"Puusaari","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.brachy.2025.11.011_bib0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0360-3016(01)02723-7","article-title":"Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects","volume":"52","author":"Jones","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2005.01.022","article-title":"Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma","volume":"63","author":"Jensen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.brachy.2025.11.011_bib0032","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0161-6420(99)90455-4","article-title":"Risk factors for radiation maculopathy and papillopathy after intraocular irradiation","volume":"106","author":"Gragoudas","year":"1999","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.brachy.2025.11.011_bib0033","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ajo.2009.11.006","article-title":"Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma","volume":"149","author":"Finger","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.brachy.2025.11.011_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.900028","article-title":"Immune senescence, immunosenescence and aging","volume":"3","author":"Lee","year":"2022","journal-title":"Front Aging"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2008.10.013","article-title":"Collaborative Ocular Melanoma Study Group. I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS report No. 30","volume":"116","author":"Boldt","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.011_bib0036","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16","volume":"108","author":"Melia","year":"2001","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.011_bib0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamaophthalmol.2016.0104","article-title":"Vision loss following episcleral brachytherapy for uveal melanoma: development of a Vision prognostication tool","volume":"134","author":"Aziz","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.brachy.2025.11.011_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0360-3016(93)90277-3","article-title":"High intensity 125-iodine (125I) plaque treatment of uveal melanoma","volume":"26","author":"Quivey","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.011_bib0039","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brachy.2015.09.013","article-title":"Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy","volume":"15","author":"Wisely","year":"2016","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.brachy.2025.11.011_bib0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ijrobp.2009.08.059","article-title":"Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study","volume":"78","author":"Saconn","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.011_bib0041","article-title":"Preliminary results of uveal melanoma treated with iodine-125 plaques: analysis of disease control and visual outcomes with 63 gy to the target volume","volume":"7","author":"Kheir","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.11.011_bib0042","article-title":"Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma","volume":"52","author":"Pors","year":"2025","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:43:27Z","timestamp":1773917007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538472125003678"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.11.011","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}